Of course.
Charlottetown is our headquarters. We have operated out of this site for the past 50 years. For the mRNA vaccine expansion, it allowed us to act quickly because it is not a greenfield expansion there, so we were able to build it onto the existing facility. We are in a position to use utilities that are already in place, which also cuts down on the total time to get this up and running.
Windsor, Nova Scotia, is our headquarters for biologic therapeutics. We are expanding it to bring on single-use, clinical-scale operational equipment that would allow us to not only produce commercial but also materials that are needed for either smaller patient populations or clinical trials.
Halifax will be our new home for the state-of-the-art process development centre. We will move most of our development teams out of the Windsor facility to Halifax and then establish there a truly remarkable facility for development, discovery and also characterization.